Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -79.37% is 71% below its 5-year average of -46.40%, near the low end of its 5-year range (-79.37%–-26.89%).
As of the fiscal period ended Tuesday, June 30, 2026. 53.09% below its 12-month average of -51.85%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -79.37%.
RETURN ON EQUITY (ROE)
-79.37%
RETURN ON EQUITY (ROE) AVG TTM
-51.85%
RETURN ON EQUITY (ROE) AVG 3Y
-47.98%
RETURN ON EQUITY (ROE) AVG 5Y
-46.40%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-53.09%
CURRENT VS 3Y AVG
-65.42%
CURRENT VS 5Y AVG
-71.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 489 covered companies
CURRENT VS SECTOR MEDIAN
-105.89%
vs the sector median at left
Erasca, Inc.
Market Cap
$4.99B
Return on Equity (ROE)
-79.37%
TTM Avg
-51.85%
3Y Avg
-47.98%
5Y Avg
-46.40%
Market Cap
$4.99B
Return on Equity (ROE)
6.24%
TTM Avg
-11.62%
3Y Avg
-98.18%
5Y Avg
-98.18%
Market Cap
$4.86B
Return on Equity (ROE)
N/A
TTM Avg
-23.20%
3Y Avg
-51.91%
5Y Avg
-56.25%
Market Cap
$5.13B
Return on Equity (ROE)
8.67%
TTM Avg
8.42%
3Y Avg
7.80%
5Y Avg
5.80%
Market Cap
$5.15B
Return on Equity (ROE)
-161.00%
TTM Avg
-110.38%
3Y Avg
-86.51%
5Y Avg
-75.97%
Market Cap
$4.80B
Return on Equity (ROE)
-2.55%
TTM Avg
-28.50%
3Y Avg
-30.36%
5Y Avg
-30.19%
Market Cap
$5.21B
Return on Equity (ROE)
-70.85%
TTM Avg
-75.76%
3Y Avg
-70.25%
5Y Avg
-57.77%
Market Cap
$4.73B
Return on Equity (ROE)
-38.51%
TTM Avg
-50.16%
3Y Avg
-65.11%
5Y Avg
-61.13%
Market Cap
$4.69B
Return on Equity (ROE)
3.43%
TTM Avg
-1.67%
3Y Avg
-7.64%
5Y Avg
-9.04%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Erasca, Inc. (ERAS) | $4.99B | -79.37% | -51.85% | -47.98% | -46.40% |
| BillionToOne, Inc. (BLLN)vs › | $4.99B | 6.24% | -11.62% | -98.18% | -98.18% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.86B | N/A | -23.20% | -51.91% | -56.25% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.13B | 8.67% | 8.42% | 7.80% | 5.80% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.15B | -161.00% | -110.38% | -86.51% | -75.97% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.80B | -2.55% | -28.50% | -30.36% | -30.19% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.21B | -70.85% | -75.76% | -70.25% | -57.77% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | -38.51% | -50.16% | -65.11% | -61.13% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 3.43% | -1.67% | -7.64% | -9.04% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.66B | -44.68% | -52.94% | -55.51% | -46.01% |
ROE
-79.4%
ROA
-66.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -79.37% |
| 2026-03-31 | -70.39% |
| 2025-12-31 | -38.30% |
| 2025-09-30 | -36.70% |
| 2025-06-30 | -34.46% |
| 2025-03-31 | -39.45% |
| 2024-12-31 | -38.17% |
| 2024-09-30 | -35.36% |
| 2024-06-30 | -35.09% |
| 2024-03-31 | -43.99% |
| 2023-12-31 | -39.48% |
| 2023-09-30 | -68.03% |
| 2023-06-30 | -64.99% |
| 2023-03-31 | -61.99% |
| 2022-12-31 | -58.95% |
| 2022-09-30 | -37.78% |
| 2022-06-30 | -37.61% |
| 2022-03-31 | -33.25% |
| 2021-12-31 | -26.89% |
| 2021-09-30 | -31.93% |
| 2021-06-30 | -62.23% |
| 2021-03-31 | -45.39% |
| 2020-12-31 | -93.24% |
